Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

NCT05136846 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT05136846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05136846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 6, 2021
Completion date
December 31, 2026
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung non-small cell carcinoma, stage ii lung cancer ajcc v8, stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, unresectable lung non-small cell carcinoma